Drug-related Pseudolymphoma: Insights from the FDA Adverse Event Reporting System
Published: 24 April 2026| Version 1 | DOI: 10.17632/k3f9cfdm7v.1
Contributor:
Van Duc LeDescription
Supplemental Table, Figure, Method
Files
Institutions
- Mayo ClinicMinnesota, Rochester
Categories
Dermatology